Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

KFSH Participa da Milken Institute Global Conference 2026 em Beverly Hills, Califórnia, como Patrocinador Prata

The King Faisal Specialist Hospital & Research Centre (KFSH) will serve as a Silver Sponsor at the upcoming Milken Institute Global Conference 2026 in Beverly Hills, California. This conference aims to unite global leaders from health, finance, technology, policy, and academia to address pressing challenges through innovation, investment, and cross-sector collaboration. Dr. Björn Zoëga, Vice-CEO of KFSH, will participate in a session focused on the future of cancer treatment, emphasizing the need for integrated, scalable, and outcome-oriented oncology models.

The significance of KFSH’s involvement lies in its commitment to evolving healthcare systems beyond isolated advancements. Dr. Zoëga will advocate for a transformative approach that prioritizes early detection, rapid intervention, and continuous learning in cancer care. This aligns with the broader goal of translating innovation into real-world clinical impact, ensuring that advancements in technology and capital are effectively integrated into patient care to enhance outcomes on a large scale.

This engagement at the Milken Institute conference signals a shift in research paradigms, particularly in oncology. By fostering dialogue among high-level decision-makers across sectors, KFSH is positioned to accelerate the development and adoption of next-generation care models. This could potentially shorten drug development timelines and enhance the scalability of effective treatments, ultimately benefiting patient populations worldwide. The recognition of KFSH as a leading institution in the Middle East and globally underscores its pivotal role in shaping the future of healthcare innovation and collaboration.

Source: globenewswire.com